利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.012 秒)

    USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS
    3.
    发明申请
    USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS 审中-公开
    作为辅助治疗剂，用抗炎剂代谢使用亚硝酸酯环化酶活化多肽（PACAP）和PACAP类似物

    公开(公告)号：US20110268789A1

    公开(公告)日：2011-11-03

    申请号：US13120862

    申请日：2009-09-25

    申请人： Min Li ,  Jerome L. Maderdrut ,  David H. Coy ,  Vecihi Batuman

    发明人： Min Li ,  Jerome L. Maderdrut ,  David H. Coy ,  Vecihi Batuman

    IPC分类号： A61K9/127 ,  A61K47/48 ,  A61K38/43 ,  A61K9/00 ,  A61K9/14 ,  A61K39/395 ,  A61P39/02 ,  A61K38/17 ,  A61K35/00

    CPC分类号： A61K38/16

    摘要： This invention relates to methods and compositions for the treatment, management or prevention of injuries to one or more of the organs of the body, such as the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of humans or other mammals caused by one or more anticancer agents. The methods of this invention consist of the administration of an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents useful for the treatment, management or prevention of injuries to the organs of the body of humans or other mammals undergoing cancer chemotherapy. Combination therapy with one or more PACAP-like compounds plus one or more anticancer agents can be used in the treatment of hematological cancers.

    摘要翻译： 本发明涉及用于治疗，管理或预防人或其它哺乳动物的一种或多种身体的器官如脑，心脏，肺，肾脏，肝脏和胃肠道的损伤的方法和组合物 通过一种或多种抗癌剂。 本发明的方法包括施用有效量的一种或多种垂体腺苷酸环化酶活化多肽（PACAP）样化合物，其包括天然人PACAP38，天然人PACAP27，天然人血管活性肠肽（VIP），它们 激动剂，类似物，片段和衍生物，具有对一种或多种PACAP / VIP受体的活性，包括其所有各种同种型。 本发明还提供本发明的一种或多种PACAP样化合物的药物组合物，其单独或与一种或多种其它预防/治疗剂组合使用，所述其它预防/治疗剂可用于治疗，管理或预防对人的身体的器官的损伤或 其他哺乳动物进行癌症化疗。 与一种或多种PACAP样化合物加上一种或多种抗癌剂的联合治疗可以用于治疗血液癌症。

    USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
    4.
    发明申请
    USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES 审中-公开
    作为ADAMYLATE CYCLASE-ACTIVATING POLYPEPTIDE（PACAP）和PACAP模拟物作为与RAPAMYCIN（mTOR）复合物的MAMMALIAN目标的CALCINEURIN或抑制剂的抑制剂的ADJUNCTIVE TREATORY的联合使用

    公开(公告)号：US20120309683A1

    公开(公告)日：2012-12-06

    申请号：US13577132

    申请日：2011-02-07

    申请人： David H. Coy ,  Jerome L. Maderdrut ,  Min Li ,  Vecihi Batuman

    发明人： David H. Coy ,  Jerome L. Maderdrut ,  Min Li ,  Vecihi Batuman

    IPC分类号： A61K38/17 ,  A61P9/00 ,  C07K14/435 ,  A61P13/12 ,  A61P1/16 ,  A61P1/00 ,  A61P25/00 ,  A61P11/00

    CPC分类号： A61K38/2235 ,  A61K38/13 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention relates to methods and compositions for the treatment, management, reduction, or prevention of injuries to one or more major organs of the body, e.g., the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of a mammal (e.g., a human) caused by one or more calcineurin or mammalian target of rapamycin (mTOR) complex inhibitors. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds to the mammal. Combination therapy with one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents, plus one or more inhibitors of either calcineurin or the mTOR complexes can be used to treat organ transplantation, autoimmune diseases, graft-versus-host disease, Behçet's disease, hematological cancers, noninfectious uveitis, sarcoidosis, tuberous sclerosis complex, acute neurological diseases, age-related neurodegenerative diseases, Huntington's disease and other CAG codon repeat expansion diseases, keratoconjunctivitis sicca, and restenosis.

    摘要翻译： 本发明涉及用于治疗，管理，减少或预防哺乳动物身体的一个或多个主要器官（例如脑，心，肺，肾，肝和胃肠道）的损伤的方法和组合物（ 由一种或多种神经磷酸酶或哺乳动物雷帕霉素靶标（mTOR）复合物抑制剂引起的人类）。 所述方法包括向哺乳动物施用有效量的一种或多种垂体腺苷酸环化酶活化多肽（PACAP）样化合物。 单独或与一种或多种其他预防/治疗剂，一种或多种钙调神经磷酸酶或mTOR复合物抑制剂的一种或多种PACAP样化合物的联合治疗可用于治疗器官移植，自身免疫疾病，移植物 冠状动脉疾病，白塞病，血液癌，非感染性葡萄膜炎，结节病，结节性硬化综合征，急性神经系统疾病，年龄相关的神经变性疾病，亨廷顿舞蹈病和其他CAG密码子重复扩张疾病，结膜性角膜结膜炎和再狭窄。